West Pharmaceutical Services, Inc. (NYSE:WST) has earned a consensus broker rating score of 1.50 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and three have given a strong buy rating to the company.

Brokerages have set a twelve-month consensus price objective of $107.50 for the company and are anticipating that the company will post $0.65 EPS for the current quarter, according to Zacks. Zacks has also assigned West Pharmaceutical Services an industry rank of 105 out of 265 based on the ratings given to related companies.

A number of research analysts recently weighed in on the company. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Friday, June 23rd. BidaskClub lowered West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $90.00 target price on shares of West Pharmaceutical Services in a report on Thursday, June 8th.

TRADEMARK VIOLATION NOTICE: “Zacks: West Pharmaceutical Services, Inc. (WST) Given $107.50 Average Target Price by Analysts” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/19/zacks-west-pharmaceutical-services-inc-wst-given-107-50-average-target-price-by-analysts-updated-updated-updated.html.

In other news, CFO William J. Federici sold 54,996 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $95.45, for a total value of $5,249,368.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel Malone sold 4,124 shares of the firm’s stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $93.31, for a total value of $384,810.44. The disclosure for this sale can be found here. Corporate insiders own 1.90% of the company’s stock.

Several large investors have recently bought and sold shares of WST. Russell Investments Group Ltd. acquired a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $308,000. Teachers Advisors LLC raised its position in shares of West Pharmaceutical Services by 8.1% in the fourth quarter. Teachers Advisors LLC now owns 65,966 shares of the medical instruments supplier’s stock valued at $5,596,000 after buying an additional 4,954 shares during the last quarter. Copper Rock Capital Partners LLC raised its position in shares of West Pharmaceutical Services by 1.7% in the first quarter. Copper Rock Capital Partners LLC now owns 343,878 shares of the medical instruments supplier’s stock valued at $28,181,000 after buying an additional 5,795 shares during the last quarter. Capstone Asset Management Co. raised its position in shares of West Pharmaceutical Services by 2.4% in the first quarter. Capstone Asset Management Co. now owns 10,160 shares of the medical instruments supplier’s stock valued at $829,000 after buying an additional 234 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its position in shares of West Pharmaceutical Services by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the medical instruments supplier’s stock valued at $1,510,000 after buying an additional 400 shares during the last quarter. Institutional investors and hedge funds own 91.34% of the company’s stock.

Shares of West Pharmaceutical Services (NYSE:WST) opened at 93.93 on Tuesday. West Pharmaceutical Services has a 52-week low of $70.17 and a 52-week high of $99.91. The firm’s 50 day moving average is $95.89 and its 200 day moving average is $88.40. The stock has a market capitalization of $6.91 billion, a price-to-earnings ratio of 38.88 and a beta of 1.12.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 27th. The medical instruments supplier reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.26. West Pharmaceutical Services had a return on equity of 14.89% and a net margin of 11.88%. The company had revenue of $387.70 million during the quarter, compared to analysts’ expectations of $380.42 million. During the same quarter in the previous year, the business earned $0.53 earnings per share. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. Equities analysts expect that West Pharmaceutical Services will post $2.73 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Wednesday, October 18th will be given a dividend of $0.14 per share. The ex-dividend date is Tuesday, October 17th. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a yield of 0.60%. West Pharmaceutical Services’s dividend payout ratio is 21.40%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.